FPR2 and Alzheimer disease: LXA4 action is mediated by LXA4 receptor (ALX) on the cellular membrane, which is known as formyl-peptide receptor-like 1 (FPRL1) [23], and activation of LXA4 signaling can well serve as a robust therapeutic target for mitigating AD-related inflammation and consequential cognitive dysfunction.